The purpose of this study is to determine if intranasal (IN) Ketorolac in combination with
oral Prochlorperazine and Diphenhydramine is non-inferior to current migraine management
which involves use of intravenous (IV) Ketorolac and oral adjuncts Prochlorperazine and
diphenhydramine for reducing pain intensity in children with migraine headaches.
The investigators hypothesize that IN ketorolac combined with these oral adjuncts is
non-inferior to IV ketorolac and oral adjuncts in reducing acute migraine headache pain by a
minimum clinically significant difference within 60 minutes of administration.